Selected article for: "acute SARS coronavirus respiratory syndrome and viral infection"
Author: Choi, Hojun; Shin, Eui-Cheol
Title: Roles of Type I and III Interferons in COVID-19
  • Cord-id: 51pfx0ds
  • Document date: 2021_5_1
    • ID: 51pfx0ds
    Snippet: Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I and III interferon (IFN) responses act as the first line of defense against viral infection and are activated by the recognition of viruses by infected cells and innate immune cells. Dysregulation of host IFN responses has been known to be associated with severe disease progression in COVID-19 patients. However, the reported results are controversial an
    Document: Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I and III interferon (IFN) responses act as the first line of defense against viral infection and are activated by the recognition of viruses by infected cells and innate immune cells. Dysregulation of host IFN responses has been known to be associated with severe disease progression in COVID-19 patients. However, the reported results are controversial and the roles of IFN responses in COVID-19 need to be investigated further. In the absence of a highly efficacious antiviral drug, clinical studies have evaluated recombinant type I and III IFNs, as they have been successfully used for the treatment of infections caused by two other epidemic coronaviruses, SARS-CoV-1 and Middle East respiratory syndrome (MERS)-CoV. In this review, we describe the strategies by which SARS-CoV-2 evades IFN responses and the dysregulation of host IFN responses in COVID-19 patients. In addition, we discuss the therapeutic potential of type I and III IFNs in COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activator kinase signal transducer and adaptive immune response: 1
    • activator transducer and acute influenza: 1, 2
    • activator transducer and acute respiratory failure: 1, 2
    • activator transducer and adaptive immune response: 1, 2, 3, 4
    • acute influenza and adaptive immune response: 1, 2, 3, 4, 5, 6
    • acute influenza and longitudinal study: 1
    • acute respiratory failure and adaptive immune response: 1, 2, 3, 4
    • acute respiratory failure and adaptive multicenter: 1
    • acute respiratory failure and longitudinal study: 1, 2, 3, 4, 5, 6
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and lung epithelial barrier: 1
    • adaptive immune response and longitudinal study: 1, 2, 3
    • adaptive immune response and lopinavir ritonavir: 1
    • longitudinal study and lopinavir ritonavir: 1